The use of targeted massively parallel sequencing to screen children with diabetes for maturity-onset diabetes of the young is more effective and less costly than the current standard care and may improve patient quality of life.
The use of targeted massively parallel sequencing to screen children with diabetes for maturity-onset diabetes of the young is more effective and less costly than the current standard care and may improve patient quality of life.